Skip to main content
SpringerLink
Log in

Das nicht muskelinvasive Urothelkarzinom der Harnblase

Neuigkeiten in der Diagnostik und Therapie

Non-muscle invasive transitional cell carcinoma of the bladder

New developments in diagnostics and therapy

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Durch die hohe Inzidenz und Rezidivrate des nicht muskelinvasiven Urothelkarzinoms kommt dieser Tumorentität eine besondere Bedeutung zu. Innovative diagnostische Verfahren stellen die „Raman spectroscopy“ und die optische Kohärenztomographie dar. Uringebundene Markersysteme spielen nach wie vor keine zentrale Rolle. An neuen therapeutischen Optionen werden die Chemohyperthermie und MMC-EMDA-Therapie vorgestellt, sowie Gemcitabine und Apaziquone als neue Substanzen für die intravesikale Therapie.

Abstract

Due to the high incidence and recurrence rate non-muscle invasive bladder cancer (NMIBC) has a relevant impact. Raman spectroscopy and optical coherence tomography represent innovative diagnostic tools. Urine markers still play a minor role in the diagnostics of NMIBC. New therapeutic options are thermochemotherapy and mitomycin-C electromotive drug administration (MMC-EMDA) as well as gemcitabine and apaziquone for intravesical administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Pashoes CL, Bottemann MF, Laskin BL et al (2002) Bladder cancer: epidemiology, diagnosis and management. Cancer Practice 10(6):311–322

    Article  Google Scholar 

  2. Bottemann MF, Pahos CL, Redaelli A et al (2003) The health economics of bladder cancer. Pharmacoeconomics 21:1315–1330

    Article  Google Scholar 

  3. Lee C, Gruschkus S, Colayco D (2011) Treatment patterns and costs of treating non-muscle invasive bladder cancer (NMIBC). Posterpräsentation 12th Annual Meeting of the Society of Urologic Oncology; November 30–December 2. Rockville, MD

  4. Schmidbauer J, Witjes F, Schmeller N et al (2004) Hexvix PCB301/01 Study group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171(1):135–138

    Article  PubMed  Google Scholar 

  5. Jichlinski P, Guillou L, Karlsen SJ et al (2003) Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer -a multicenter study. J Urol 170(1):226–229

    Article  PubMed  Google Scholar 

  6. Hungerhuber E, Stepp H, Kriegmair M et al (2007) Seven years‘ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69(2):260–264

    Article  PubMed  Google Scholar 

  7. Kausch I, Sommerauer M, Montorsi F et al (2010) Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 57(4):595–606

    Article  PubMed  Google Scholar 

  8. Mowatt G, N’Dow J, Vale L et al (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care 27(1):3–10

    Article  PubMed  Google Scholar 

  9. Cauberg EC, de Bruin DM, Faber DJ et al (2009) A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur Urol 56(2):287–296

    Article  PubMed  Google Scholar 

  10. de Jong BW, Schut TC, Maquelin K et al (2006) Discrimination between nontumor bladder tissue and tumor by Raman spectroscopy. Anal Chem 78(22):7761–7769

    Article  Google Scholar 

  11. Crow P, Uff JS, Farmer JA et al (2004) The use of Raman spectroscopy to identify and characterize transitional cell carcinoma in vitro. BJU Int 93(9):1232–1236

    Article  PubMed  CAS  Google Scholar 

  12. Tearney GJ, Brezinski ME, Southern JF et al (1997) Optical biopsy in human urologic tissue using optical coherence tomography. J Urol 157:1915–1919

    Article  PubMed  CAS  Google Scholar 

  13. Jesser CA, Boppart SA, Pitris C et al (1999) High resolution imaging of transitional cell carcinoma with optical coherence tomography: feasibility for the evaluation of bladder pathology. Br J Radiol 72:1170–1176

    PubMed  CAS  Google Scholar 

  14. Wang Z, Lee CS, Waltzer WC et al (2007) In vivo bladder imaging with microelectromechanical-systems-based endoscopic spectral domain optical coherence tomography. J Biomed Opt 12:034009

    Article  PubMed  Google Scholar 

  15. Hermes B, Spöler F, Naami A et al (2008) Visualization of the basement membrane zone of the bladder by optical coherence tomography: feasibility of noninvasive evaluation of tumor invasion. Urology 72(3):677–681

    Article  PubMed  Google Scholar 

  16. Manyak MJ, Gladkova ND, Makari JH et al (2005) Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. J Endourol 19(5):570–574

    Article  PubMed  Google Scholar 

  17. Zagaynova EV, Streltsova OS, Gladkova ND et al (2002) In vivo optical coherence tomography feasibility for bladder disease. J Urol 167(3):1492–1496

    Article  PubMed  Google Scholar 

  18. Goh AC, Tresser NJ, Shen SS et al (2008) Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 72(1):133–137

    Article  PubMed  Google Scholar 

  19. Lingley-Papadopoulos CA, Loew MH, Manyak MJ et al (2008) Computer recognition of cancer in the urinary bladder using optical coherence tomography and texture analysis. J Biomed Opt 13(2):024003

    Article  PubMed  Google Scholar 

  20. Lokeshwar VB, Habuchi T, Grossman HB et al (2005) Bladder tumour markers beyond cytology: international consensus panel on bladder tumour markers. Urology 66(6 Suppl 1):35–63

    Article  PubMed  Google Scholar 

  21. Glas AS, Roos D, Deutekom M et al (2003) Tumour markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 169(6):1975–1982

    Article  PubMed  Google Scholar 

  22. Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumour markers versus cytology: results of a comprehensive literature review and meta-analysis. Urology 61(1):109–118

    Article  PubMed  Google Scholar 

  23. Van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47(6):736–748

    Article  Google Scholar 

  24. Van Rhijn BWG, van der Poel HG, van der Kwast HG (2009) Cytology and urinary markers for the diagnosis of bladder cancer. Eur Urol Suppl 8:536–541

    Article  Google Scholar 

  25. Tilki D, Burger M, Dalbagni G, Grossman HB et al (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60(3):484–492

    Article  PubMed  Google Scholar 

  26. Mowatt G, Zhu S, Kilonzo M, Boachie C et al (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 14(4):1–331

    CAS  Google Scholar 

  27. Babjuk M, Oostelinck W, Sylvester R et al (2011) EAU Guidelines on non-muscle-invasive urothelial carcinoma oft the bladder, the 2011 update. Eur Urol 59:997–1008

    Article  PubMed  Google Scholar 

  28. Brausi M, Witjes JA, Lamm D et al (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. J Urol 186:2158–2167

    Article  PubMed  Google Scholar 

  29. Sylvester R, Oostelinck W, van der Meijden A (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 171:2186–2190

    Article  PubMed  Google Scholar 

  30. Gudjonsson S, Adell L, Merdasa F et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomized multicentre study. Eur Urol 55:773–780

    Article  PubMed  Google Scholar 

  31. Herr HW, Donat SM, Dalbagni G (2002) Correlation of cystoscopy with histology of histology of recurrent papillary tumors of the bladder. J Urol 168:987

    Article  Google Scholar 

  32. Sylvester RJ, Brausi MA, de Reijke TM et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57:766–773

    Article  PubMed  Google Scholar 

  33. Malmström P-U, Sylvester RJ, Witjes JA et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical Mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247–256

    Article  PubMed  Google Scholar 

  34. Colombo R, Salonia A, Engelstein D et al (2011) Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-c alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU 107:912–918

    Article  CAS  Google Scholar 

  35. Halachmi S, Moskovitz B, Colombo R et al (2011) Intravesical mitomycin C combined with hyperthermia for patients with T1 GIII transitional cell carcinoma of the bladder. Urol Oncol 29:259–264

    Article  PubMed  CAS  Google Scholar 

  36. Di Stasi SM, Valenti M, Vespasiani G et al (2011) Electromitive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomized controlled trial. Lancet Oncol 12:971–979

    Google Scholar 

  37. Shelly MD, Jones G, Kynaston HG et al (2012) Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int 109:496–505

    Article  Google Scholar 

  38. van der Heijden AG, Moonen PM, Cornel EB et al (2006) Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176(4 Pt 1):1349–1353

    Article  Google Scholar 

  39. Hendricksen K, van der Heijden AG, Cornel EB et al (2009) Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 27(3):337–342

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehung/en hin: Prof. Jocham Beirat für GE Healthcare bzw. IPSEN Pharma.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, UK-SH Campus Lübeck, Ratzeburgerallee 160, 23568, Lübeck, Deutschland

    M. Sommerauer, D. Jocham & J.M. Laturnus

Authors
  1. M. Sommerauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Jocham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.M. Laturnus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Sommerauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sommerauer, M., Jocham, D. & Laturnus, J. Das nicht muskelinvasive Urothelkarzinom der Harnblase. Urologe 51, 791–797 (2012). https://doi.org/10.1007/s00120-012-2897-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-012-2897-3

Schlüsselwörter

Keywords

Search

Navigation